Your browser is no longer supported. Please, upgrade your browser.
Settings
BHVN Biohaven Pharmaceutical Holding Company Ltd. daily Stock Chart
BHVN [NYSE]
Biohaven Pharmaceutical Holding Company Ltd.
Index- P/E- EPS (ttm)-12.27 Insider Own9.10% Shs Outstand59.68M Perf Week-5.58%
Market Cap5.37B Forward P/E- EPS next Y-9.67 Insider Trans-16.74% Shs Float49.67M Perf Month17.76%
Income-698.30M PEG- EPS next Q-2.99 Inst Own- Short Float14.47% Perf Quarter51.61%
Sales28.50M P/S188.49 EPS this Y-77.40% Inst Trans0.83% Short Ratio12.69 Perf Half Y42.04%
Book/sh-3.56 P/B- EPS next Y22.10% ROA-134.10% Target Price90.30 Perf Year58.47%
Cash/sh9.29 P/C9.84 EPS next 5Y- ROE- 52W Range26.56 - 100.77 Perf YTD67.82%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-9.34% Beta1.12
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin72.90% 52W Low243.98% ATR4.20
Employees647 Current Ratio3.30 Sales Q/Q- Oper. Margin- RSI (14)58.22 Volatility5.31% 5.23%
OptionableYes Debt/Eq- EPS Q/Q-60.70% Profit Margin- Rel Volume0.39 Prev Close89.62
ShortableYes LT Debt/Eq- EarningsNov 09 BMO Payout- Avg Volume566.28K Price91.36
Recom1.70 SMA202.83% SMA5016.69% SMA20050.48% Volume219,953 Change1.94%
Apr-17-20Initiated Cowen Outperform $45
Feb-10-20Downgrade Oppenheimer Outperform → Perform
Feb-06-20Initiated Mizuho Buy
Nov-22-19Initiated Wedbush Outperform
Jun-25-19Reiterated Canaccord Genuity Buy $89 → $84
May-06-19Initiated Goldman Buy $92
Apr-09-19Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-04-19Reiterated Needham Buy $48 → $56
Jul-03-18Reiterated Needham Buy $36 → $48
Jul-02-18Reiterated Needham Buy $36 → $48
Apr-05-18Downgrade Barclays Overweight → Equal Weight $30 → $25
Feb-22-18Reiterated Canaccord Genuity Buy $30 → $39
Dec-15-17Initiated Canaccord Genuity Buy $30
Oct-03-17Reiterated Needham Buy $43 → $36
Nov-30-20 08:00AM  
Nov-22-20 09:32PM  
Nov-19-20 09:51AM  
Nov-16-20 09:00AM  
07:30AM  
Nov-11-20 04:30PM  
Nov-10-20 10:39AM  
Nov-09-20 08:32AM  
08:00AM  
08:00AM  
06:30AM  
Nov-06-20 08:34AM  
Nov-02-20 09:15AM  
Oct-30-20 06:23PM  
Oct-29-20 12:51PM  
Oct-27-20 12:28PM  
Oct-15-20 11:41AM  
Oct-14-20 07:30AM  
Oct-04-20 09:19AM  
09:19AM  
Sep-28-20 07:00AM  
Sep-21-20 08:00AM  
Sep-10-20 07:00AM  
Sep-08-20 08:30AM  
04:34AM  
Sep-02-20 01:19PM  
Aug-10-20 11:55AM  
07:45AM  
Aug-07-20 09:47AM  
09:37AM  
Aug-06-20 01:42PM  
Aug-05-20 05:00PM  
Aug-03-20 08:00AM  
Jul-21-20 07:30AM  
Jul-16-20 07:52AM  
05:45AM  
Jul-15-20 11:41AM  
09:52AM  
07:30AM  
Jul-13-20 10:08AM  
Jul-08-20 07:30AM  
Jun-24-20 07:00AM  
Jun-16-20 07:00AM  
Jun-10-20 07:00AM  
Jun-08-20 02:13AM  
Jun-01-20 04:05PM  
May-28-20 06:46AM  
May-21-20 07:30AM  
May-18-20 07:30AM  
May-15-20 07:33AM  
May-07-20 04:10PM  
May-04-20 08:47AM  
Apr-27-20 07:30AM  
Apr-16-20 05:42PM  
07:30AM  
Apr-09-20 10:01AM  
07:30AM  
Apr-07-20 07:48AM  
07:30AM  
Mar-31-20 07:33AM  
Mar-30-20 07:30AM  
Mar-29-20 08:21PM  
Mar-23-20 07:30AM  
Mar-18-20 07:30AM  
Mar-13-20 07:30AM  
Mar-12-20 04:30PM  
Mar-04-20 09:55AM  
Feb-28-20 07:28AM  
Feb-27-20 04:11PM  
Feb-25-20 04:45PM  
Feb-14-20 07:33AM  
Feb-11-20 11:27AM  
Feb-10-20 04:17PM  
08:10AM  
07:30AM  
07:25AM  
Feb-06-20 07:33AM  
Feb-04-20 10:22AM  
Jan-31-20 05:00PM  
Jan-30-20 09:02AM  
Jan-29-20 07:34AM  
Jan-28-20 05:13PM  
Jan-23-20 07:24AM  
Jan-19-20 10:23AM  
Jan-16-20 01:45PM  
Dec-26-19 11:45AM  
08:40AM  
Dec-18-19 07:33AM  
Dec-17-19 07:30AM  
Dec-15-19 07:41AM  
Dec-06-19 04:32PM  
08:29AM  
07:51AM  
07:39AM  
07:30AM  
Dec-05-19 05:43PM  
Dec-04-19 08:31PM  
Dec-02-19 07:33AM  
Nov-13-19 01:00PM  
Nov-06-19 09:02AM  
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Conway CharlesChief Scientific OfficerNov 25Option Exercise0.003,00008,639Nov 27 09:47 PM
Coric VladChief Executive OfficerNov 25Option Exercise0.0010,950016,935Nov 27 09:47 PM
Engelhart JamesChief Financial OfficerNov 25Option Exercise0.003,70008,222Nov 27 09:47 PM
Gentile KimberlySVP, Clinical OperationsNov 25Option Exercise0.003,75007,389Nov 27 09:48 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseNov 25Option Exercise0.003,00004,755Nov 27 09:48 PM
Stock ElyseChief Medical OfficerNov 25Option Exercise0.003,37505,219Nov 27 09:48 PM
Tilton JohnChief Commercial OfficerNov 25Option Exercise0.001,25002,020Nov 27 09:48 PM
CHILDS JOHN WDirectorNov 23Buy89.555,000447,7372,516,938Nov 23 08:40 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseNov 02Option Exercise50.7230,0001,521,60031,755Nov 04 08:31 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseNov 02Sale76.2230,0002,286,6761,755Nov 04 08:31 PM
Bailey GregoryDirectorOct 23Sale78.9110,403820,8662,545,658Oct 23 09:25 PM
Bailey GregoryDirectorOct 22Sale79.4724,5661,952,3522,556,061Oct 23 09:25 PM
Bailey GregoryDirectorOct 19Sale78.984,554359,6552,580,627Oct 21 09:24 PM
Bailey GregoryDirectorOct 16Sale78.883,748295,6382,585,181Oct 21 09:24 PM
Bailey GregoryDirectorOct 12Sale78.876,729530,7402,588,929Oct 14 09:31 PM
Gentile KimberlySVP, Clinical OperationsOct 08Option Exercise9.2923,500218,31527,139Oct 09 06:42 PM
Gentile KimberlySVP, Clinical OperationsOct 08Sale76.3423,5001,794,0823,639Oct 09 06:42 PM
CHILDS JOHN WDirectorSep 21Buy59.253,322196,8292,511,938Sep 22 09:51 PM
CHILDS JOHN WDirectorSep 11Buy59.006,678393,9842,508,616Sep 14 08:49 PM
CHILDS JOHN WDirectorAug 11Buy61.5425,0001,538,4852,501,938Aug 12 06:25 PM
Berman RobertSpecial Projects & Med OvrsghtJul 08Option Exercise0.6158,40435,62658,745Jul 10 09:15 PM
Bailey GregoryDirectorJul 08Sale75.2250,0003,760,7652,595,658Jul 10 09:16 PM
Berman RobertSpecial Projects & Med OvrsghtJul 08Sale75.2558,4044,394,890341Jul 10 09:15 PM
Bailey GregoryDirectorJun 24Sale69.863,995279,0902,645,658Jun 25 09:49 PM
Berman RobertSpecial Projects & Med OvrsghtJun 23Option Exercise0.614,2962,6214,637Jun 25 09:49 PM
Berman RobertSpecial Projects & Med OvrsghtJun 23Sale75.054,296322,431341Jun 25 09:49 PM
Bailey GregoryDirectorJun 23Sale74.15101,6437,536,4322,649,653Jun 25 09:49 PM
Bailey GregoryDirectorJun 22Sale73.2480,3315,883,1752,751,296Jun 22 09:58 PM
Berman RobertSpecial Projects & Med OvrsghtJun 19Option Exercise0.619866011,327Jun 22 09:57 PM
Bailey GregoryDirectorJun 19Sale71.22164,03111,682,7572,831,627Jun 22 09:58 PM
Berman RobertSpecial Projects & Med OvrsghtJun 19Sale75.0798674,016341Jun 22 09:57 PM
Berman RobertSpecial Projects & Med OvrsghtJun 18Option Exercise2.6461,314162,15261,655Jun 22 09:57 PM
Berman RobertSpecial Projects & Med OvrsghtJun 18Sale75.2761,3144,615,290341Jun 22 09:57 PM
Gentile KimberlySVP, Clinical OperationsJun 17Option Exercise5.604002,2404,039Jun 18 09:51 PM
Gentile KimberlySVP, Clinical OperationsJun 17Option Exercise5.6024,000134,40027,639Jun 17 09:55 PM
Gentile KimberlySVP, Clinical OperationsJun 17Sale70.2024,0001,684,8703,639Jun 17 09:55 PM
Gentile KimberlySVP, Clinical OperationsJun 17Sale70.2040028,0813,639Jun 18 09:51 PM
Doogan DeclanDirectorJun 16Sale68.2260,0004,092,959626,002Jun 17 09:55 PM
Doogan DeclanDirectorJun 15Sale66.7380,0005,338,791686,002Jun 17 09:55 PM
Stock ElyseChief Medical OfficerJun 12Option Exercise25.9036,966957,51138,810Jun 12 09:51 PM
Stock ElyseChief Medical OfficerJun 12Sale64.8336,9662,396,5021,844Jun 12 09:51 PM
Doogan DeclanDirectorJun 12Sale64.7380,0005,178,453766,002Jun 12 08:09 PM
Engelhart JamesChief Financial OfficerJun 11Option Exercise9.2919,772183,68224,294Jun 12 05:19 PM
Doogan DeclanDirectorJun 11Sale63.4180,0005,072,600846,002Jun 12 08:09 PM
Engelhart JamesChief Financial OfficerJun 11Sale63.4319,7721,254,0574,522Jun 12 05:19 PM
Tilton JohnChief Commercial OfficerJun 10Option Exercise9.2952,000483,08052,770Jun 12 05:19 PM
Engelhart JamesChief Financial OfficerJun 10Option Exercise4.7653,953257,07358,475Jun 12 05:19 PM
Engelhart JamesChief Financial OfficerJun 10Sale67.0753,9533,618,5454,522Jun 12 05:19 PM
Tilton JohnChief Commercial OfficerJun 10Sale67.3852,0003,504,001770Jun 12 05:19 PM
Gentile KimberlySVP, Clinical OperationsJun 08Option Exercise5.606003,3604,239Jun 10 09:24 PM
Gentile KimberlySVP, Clinical OperationsJun 08Sale70.0560042,0273,639Jun 10 09:24 PM
Bailey GregoryDirectorJun 05Option Exercise4.69438,2002,053,9383,025,801Jun 08 05:15 PM
CHILDS JOHN WDirectorApr 07Sale31.91200,0006,381,0322,476,938Apr 08 09:42 PM
CHILDS JOHN WDirectorApr 06Sale31.25150,0004,686,9372,676,938Apr 08 09:42 PM
AGUIAR ERICDirectorJan 22Option Exercise35.592,02171,9213,271Jan 24 06:43 PM
AGUIAR ERICDirectorJan 22Sale56.482,021114,1521,250Jan 24 06:43 PM
AGUIAR ERICDirectorJan 09Option Exercise9.2930,000278,70030,000Jan 10 07:46 PM
Gentile KimberlySVP, Clinical OperationsJan 09Option Exercise31.321,59049,8063,639Jan 10 07:46 PM
AGUIAR ERICDirectorJan 09Sale56.3930,0001,691,7000Jan 10 07:46 PM
Stock ElyseChief Medical OfficerJan 08Option Exercise55.9193752,388937Jan 10 07:46 PM
AGUIAR ERICDirectorJan 08Option Exercise55.911,25069,8881,250Jan 10 07:46 PM
Berman RobertSpecial Projects & Med OvrsghtDec 30Option Exercise0.61125,00076,250125,341Dec 31 07:33 PM
Berman RobertSpecial Projects & Med OvrsghtDec 30Sale53.22125,0006,652,052341Dec 31 07:33 PM
Stock ElyseChief Medical OfficerDec 18Option Exercise0.003,37503,375Dec 20 09:41 PM
Conway CharlesChief Scientific OfficerDec 18Option Exercise0.003,00007,000Dec 20 09:42 PM
Berman RobertSpecial Projects & Med OvrsghtDec 18Option Exercise0.006250625Dec 20 09:42 PM
Gentile KimberlySVP, Clinical OperationsDec 18Option Exercise0.003,75003,750Dec 20 09:40 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseDec 18Option Exercise0.003,00003,000Dec 20 09:40 PM
Tilton JohnCCO-Rare & Neurologic DisorderDec 18Option Exercise0.001,25001,250Dec 20 09:41 PM
Coric VladChief Executive OfficerDec 18Option Exercise0.0010,950010,950Dec 20 09:39 PM
Engelhart JamesChief Financial OfficerDec 18Option Exercise0.003,70006,200Dec 20 09:39 PM
AGUIAR ERICDirectorDec 16Option Exercise20.793,53773,5343,537Dec 18 09:39 PM
AGUIAR ERICDirectorDec 16Sale55.133,537194,9850Dec 18 09:39 PM
AGUIAR ERICDirectorDec 09Option Exercise20.794,07284,6574,072Dec 11 09:43 PM
AGUIAR ERICDirectorDec 09Sale55.114,072224,4110Dec 11 09:43 PM